1
|
Oliveira C, Granja S, Neves NM, Reis RL, Baltazar F, Silva TH, Martins A. Fucoidan from Fucus vesiculosus inhibits new blood vessel formation and breast tumor growth in vivo. Carbohydr Polym 2019; 223:115034. [PMID: 31426965 DOI: 10.1016/j.carbpol.2019.115034] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 04/30/2019] [Accepted: 06/26/2019] [Indexed: 12/21/2022]
Abstract
Fucoidan is a marine-origin sulfated polysaccharide that can show anticancer activity, to which both pro- and anti-angiogenic responses have been reported. Due to this unpredictability, the angiogenic potential of an effective anticancer crude fucoidan (CF), at a concentration of 0.5 mg mL-1, was evaluated. Tube formation assays demonstrated that CF, either administered while endothelial cells seeding or after their adhesion, migration and organization, inhibited or disrupted the formation of tubular-like structures, respectively. Although CF did not significantly reduced vascular endothelial growth factor (VEGF) secretion, it significantly reduced the expression of platelet-derived growth factor (PDGF), compromising the blood vessels maturation. Two chicken embryo chorioallantoic membrane (CAM) assays were performed: one without tumor (CAM I) and the other with an onplanted tumor mass (CAM II); the CF injection reduced the number of blood of vessels and significantly decreased the tumor size, respectively. In vitro and in vivo results support the effectiveness of fucoidan as a natural antitumor therapeutic agent.
Collapse
Affiliation(s)
- Catarina Oliveira
- 3B´s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017, Barco, Guimarães, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal
| | - Sara Granja
- ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
| | - Nuno M Neves
- 3B´s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017, Barco, Guimarães, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal; The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, 4805-017, Barco, Guimarães, Portugal
| | - Rui L Reis
- 3B´s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017, Barco, Guimarães, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal; The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, 4805-017, Barco, Guimarães, Portugal
| | - Fátima Baltazar
- ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
| | - Tiago H Silva
- 3B´s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017, Barco, Guimarães, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal
| | - Albino Martins
- 3B´s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017, Barco, Guimarães, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal.
| |
Collapse
|
2
|
TIMP-1 overexpression in lung carcinoma enhances tumor kinetics and angiogenesis in brain metastasis. J Neuropathol Exp Neurol 2015; 74:293-304. [PMID: 25756591 DOI: 10.1097/nen.0000000000000175] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Tissue inhibitors of matrix metalloproteinase (TIMP) orchestrate many biologic activities, including inhibition of matrix metalloproteinase activity, activation of pro-matrix metalloproteinases, and regulation of cell proliferation, angiogenesis, and apoptosis induction. Tissue inhibitors of matrix metalloproteinase can play a protective role during tumor invasion and metastasis, but elevated TIMP messenger RNA levels have also been associated with aggressive cancers and poor clinical outcome. We examined the potential roles of TIMP-1 in H2009 lung adenocarcinoma cells and in cells transfected with a human TIMP-1-overexpressing vector (HB-6 and HB-1). Tumors resulting from the implantation of parental cell lines and transfected HB-1 cells into the brains of nude mice had a typical carcinoma profile, but human TIMP-1-overexpressing tumors showed enhanced tumor kinetics and focally more infiltrative features; vessel density assessed with anti-CD31 immunohistochemistry was also greater within HB-1 tumor implants. Similar effects on HB-6 and HB-1 cells versus parental cell lines and empty vector clones were observed in endothelial cell assays. Anchorage-independent growth and invasion through Matrigel were also increased in TIMP-1-overexpressing cells. Together, these results indicate tumor-promoting functions of TIMP-1 through alterations in angiogenesis, increased tumorigenicity, and invasive behavior. Although matrix metalloproteinase inhibition has been the traditionally identified function of TIMP-1, matrix metalloproteinase-independent interactions may contribute to the growth of metastatic carcinomas in the brain.
Collapse
|
3
|
Zheng Y, Chen H, Zeng X, Liu Z, Xiao X, Zhu Y, Gu D, Mei L. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy. NANOSCALE RESEARCH LETTERS 2013; 8:161. [PMID: 23570619 PMCID: PMC3639870 DOI: 10.1186/1556-276x-8-161] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2012] [Accepted: 01/17/2013] [Indexed: 05/20/2023]
Abstract
The efficient delivery of therapeutic genes into cells of interest is a critical challenge to broad application of non-viral vector systems. In this research, a novel TPGS-b-(PCL-ran-PGA) nanoparticle modified with polyethyleneimine was applied to be a vector of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and endostatin for cervical cancer gene therapy. Firstly, a novel biodegradable copolymer, TPGS-b-(PCL-ran-PGA), was synthesized and characterized. The nanoparticles were fabricated by an emulsion/solvent evaporation method and then further modified with polyethyleneimine (PEI) carrying TRAIL and/or endostatin genes. The uptake of pIRES2-EGFP and/or pDsRED nanoparticles by HeLa cells were observed by fluorescence microscopy and confocal laser scanning microscopy. The cell viability of TRAIL/endostatin-loaded nanoparticles in HeLa cells was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Severe combined immunodeficient mice carrying HeLa tumor xenografts were treated in groups of six including phosphate-buffered saline control, blank TPGS-b-(PCL-ran-PGA) nanoparticles, blank TPGS-b-(PCL-ran-PGA)/PEI nanoparticles, and three types of gene nanoparticles. The activity was assessed using average increase in survival time, body weight, and solid tumor volume. All the specimens were then prepared as formalin-fixed and paraffin-embedded tissue sections for hematoxylin-eosin staining. The data showed that the nanoparticles could efficiently deliver plasmids into HeLa cells. The cytotoxicity of the HeLa cells was significantly increased by TRAIL/endostatin-loaded nanoparticles when compared with control groups. The use of TPGS in combination with TRAIL and endostatin had synergistic antitumor effects. In conclusion, the TRAIL/endostatin-loaded nanoparticles offer considerable potential as an ideal candidate for in vivo cancer gene delivery.
Collapse
Affiliation(s)
- Yi Zheng
- The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotechnology and BioMedicine and Division of Life Science and Health, Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, People's Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People's Republic of China
| | - Hongbo Chen
- The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotechnology and BioMedicine and Division of Life Science and Health, Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, People's Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People's Republic of China
| | - Xiaowei Zeng
- The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotechnology and BioMedicine and Division of Life Science and Health, Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, People's Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People's Republic of China
| | - Zhigang Liu
- School of Medicine, Shenzhen University, Shenzhen, 518060, People's Republic of China
| | - Xiaojun Xiao
- School of Medicine, Shenzhen University, Shenzhen, 518060, People's Republic of China
| | - Yongqiang Zhu
- The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotechnology and BioMedicine and Division of Life Science and Health, Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, People's Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People's Republic of China
| | - Dayong Gu
- The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotechnology and BioMedicine and Division of Life Science and Health, Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, People's Republic of China
- Institute of Disease Control and Prevention, Shenzhen Entry-Exit Inspection and Quarantine Bureau, Shenzhen, 518045, People's Republic of China
| | - Lin Mei
- The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotechnology and BioMedicine and Division of Life Science and Health, Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, People's Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People's Republic of China
| |
Collapse
|
4
|
Qiu B, Ji M, Song X, Zhu Y, Wang Z, Zhang X, Wu S, Chen H, Mei L, Zheng Y. Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer. NANOSCALE RESEARCH LETTERS 2012; 7:666. [PMID: 23216701 PMCID: PMC3598810 DOI: 10.1186/1556-276x-7-666] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 11/12/2012] [Indexed: 05/28/2023]
Abstract
Cervical cancer remains a major problem in women's health worldwide. In this research, a novel biodegradable d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) (TPGS-b-(PCL-ran-PGA)) nanoparticle (NP) was developed as a co-delivery system of docetaxel and endostatin for the synergistic treatment of cervical cancer. Docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs were prepared and further modified by polyethyleneimine for coating plasmid pShuttle2-endostatin. All NPs were characterized in size, surface charge, morphology, and in vitro release of docetaxel and pDNA. The uptake of coumarin 6-loaded TPGS-b-(PCL-ran-PGA)/PEI-pDsRED by HeLa cells was observed via fluorescent microscopy and confocal laser scanning microscopy. Endostatin expression in HeLa cells transfected by TPGS-b-(PCL-ran-PGA)/PEI-pShuttle2-endostatin NPs was detected using Western blot analysis, and the cell viability of different NP-treated HeLa cells was determined by MTT assay. The HeLa cells from the tumor model, nude mice, were treated with various NPs including docetaxel-loaded-TPGS-b-(PCL-ran-PGA)/PEI-endostatin NPs, and their survival time, tumor volume and body weight were monitored during regimen process. The tumor tissue histopathology was analyzed using hematoxylin and eosin staining, and microvessel density in tumor tissue was evaluated immunohistochemically. The results showed that the TPGS-b-(PCL-ran-PGA)/PEI NPs can efficiently and simultaneously deliver both coumarin-6 and plasmids into HeLa cells, and the expression of endostatin was verified via Western blot analysis. Compared with control groups, the TPGS-b-(PCL-ran-PGA)/PEI-pShuttle2-endostatin NPs significantly decreased the cell viability of HeLa cells (p < 0.01), inhibited the growth of tumors, and even eradicated the tumors. The underlying mechanism is attributed to synergistic anti-tumor effects by the combined use of docetaxel, endostatin, and TPGS released from NPs. The TPGS-b-(PCL-ran-PGA) NPs could function as multifunctional carrier for chemotherapeutic drugs and genetic material delivery, and offer considerable potential as an ideal candidate for in vivo cancer therapy.
Collapse
Affiliation(s)
- Bo Qiu
- Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
| | - Minghui Ji
- Southern Medical University, Guangzhou, 510515, People’s Republic of China
| | - Xiaosong Song
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
| | - Yongqiang Zhu
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
| | - Zhongyuan Wang
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
| | - Xudong Zhang
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
| | - Shu Wu
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
| | - Hongbo Chen
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
| | - Lin Mei
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
- L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, China
| | - Yi Zheng
- The Shenzhen Key Lab of Gene and Antibody Therapy, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, People’s Republic of China
- School of Life Sciences, Tsinghua University, Beijing, 100084, People’s Republic of China
- L401, Tsinghua Campus, Xili University Town, Shenzhen, Guangdong Province, 518055, China
| |
Collapse
|
5
|
Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011; 11:277. [PMID: 21708009 PMCID: PMC3144457 DOI: 10.1186/1471-2407-11-277] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2010] [Accepted: 06/27/2011] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND HER-2/neu and VEGF expression is correlated with disease behaviors in various cancers. However, evidence for their expression in colon cancer is rather contradictory both for the protein expression status and prognostic value. HER-2/neu is found to participate in VEGF regulation, and has known correlation with VEGF expression in some tumors. In this study, we investigated HER-2/neu and VEGF expression in Chinese colon patients and explored whether there was any correlation between their expression patterns. METHODS HER-2/neu and VEGF were investigated immunohistochemically using tumor samples obtained from 317 colon cancer patients with all tumor stages. Correlation of the degree of staining with clinicopathological parameters and survival was investigated. RESULTS Positive expression rates of HER-2/neu and VEGF in colon cancer were 15.5% and 55.5% respectively. HER-2/neu expression was significantly correlated with tumor size and distant metastases (P < 0.05), but was not an independent prognostic marker of survival (P > 0.05). Expression of VEGF was significantly correlated with tumor size, tumor stage, lymph node metastases, and distant metastases (P < 0.05). The 5-year survival rate in patients with negative and positive VEGF expression was 70.2% and 61.9% respectively; the difference was not statistically significant (P = 0.146). No correlation between HER-2/neu and VEGF expression was detected (P = 0.151). CONCLUSIONS HER-2/neu and VEGF are not important prognostic markers of colon cancer. The present results do not support any association between HER2/neu and VEGF expression in this setting.
Collapse
Affiliation(s)
- Qingguo Li
- Department of General Surgery, First Clinic Medical School of Yangzhou University, Yangzhou, China
| | | | | | | |
Collapse
|
6
|
Zhuang HQ, Yuan ZY. Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett 2009; 282:9-13. [PMID: 19136200 DOI: 10.1016/j.canlet.2008.12.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2008] [Revised: 12/05/2008] [Accepted: 12/08/2008] [Indexed: 10/21/2022]
Abstract
Endostatin has been demonstrated to represent a promising novel medicine to treat malignant tumors, and it may be more effective when combined with conventional treatment. Meanwhile, a promising area of research in radiation oncology is the integration of molecular targeting agents to improve the effectiveness of radiotherapy (RT) in the control of primary tumor. Antiangiogenic agents are one such class of targeted therapies and have shown promise in both laboratory and clinical experiments. Endostatin in combination with RT has feasibility; but it also has lots of problems. Further understanding of the mechanisms is needed.
Collapse
Affiliation(s)
- Hong-Qing Zhuang
- Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China
| | | |
Collapse
|
7
|
Discrepancy Between the Dynamic Computed Tomography and T2* Magnetic Resonance Perfusion Imaging in Brain Tumors. J Comput Assist Tomogr 2007; 31:896-900. [DOI: 10.1097/rct.0b013e31803e8c67] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Gerrah R, Fogel M, Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol 2004; 94:25-9. [PMID: 14996470 DOI: 10.1016/j.ijcard.2003.03.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2002] [Accepted: 03/08/2003] [Indexed: 11/21/2022]
Abstract
BACKGROUND Vascular Endothelial Growth Factor (VEGF) is an important angiogenesis factor involved in pathophysiology of cardiovascular diseases. Controlling this factor's level in the serum might have significant prognostic outcomes. METHODS Twenty-four patients undergoing coronary artery bypass grafting were prospectively categorized into two groups according to aspirin administration before surgery. Vascular Endothelial Growth Factor levels were compared and correlated and adjusted with platelets count between two groups in the serum, before and after the surgery. Serum creatine kinase (CK) levels were determined before and after the operation in parallel to other clinical data. RESULTS Vascular Endothelial Growth Factor levels were significantly lower in patients of the aspirin group compared to those of the non-aspirin group; 94+/-61 vs. 241+/-118 pg/ml, p=0.0003, respectively, this-despite an absence of difference in the platelet count between the groups. These titers decreased postoperatively in both groups, 94+/-61 to 10+/-9 pg/ml, p=0.001 in aspirin group and from 241+/-118 to 84+/-54 pg/ml, p=0.001 in control group. Serum creatine kinase levels were higher in the non-aspirin group, 214+/-83 u/l compared to 70+/-32 u/l in the aspirin group. Creatine kinase levels increased significantly postoperatively in both groups; however, the aspirin group had a significantly lower creatine kinase levels compared to non-aspirin group, 107+/-51 vs. 401+/-127 u/l, respectively, p=<0.0001. A significant correlation was seen between VEGF levels and platelets count in both groups, r=0.5. CONCLUSIONS Aspirin treated patients have lower Vascular Endothelial Growth Factor titer levels in the perioperative course. This difference between the aspirin and the non-aspirin group is not accounted for by the platelets count.
Collapse
Affiliation(s)
- Rabin Gerrah
- Department of Cardiothoracic Surgery, Hadassah University Hospital, P.O.B. 12000, Jerusalem 91120, Israel.
| | | | | |
Collapse
|
9
|
Kassner A, Roberts TPL. Beyond perfusion: cerebral vascular reactivity and assessment of microvascular permeability. Top Magn Reson Imaging 2004; 15:58-65. [PMID: 15057173 DOI: 10.1097/00002142-200402000-00006] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Beyond perfusion, several other related methods are under development for a more complete characterization of different aspects of vascular function. This article will be divided into two parts focusing on two emerging imaging-based assays of vascular status: 1) the cerebrovascular reactivity to a vasodilatory stimulus and 2) the microvascular permeability to a blood-borne MR-visible tracer. Taken together, these approaches can be seen to extend our interrogation of vascular functional and structural integrity and to offer promising clinical and experimental applications.
Collapse
Affiliation(s)
- Andrea Kassner
- Department of Medical Imaging, University Health Network & University of Toronto, Ontario, Canada.
| | | |
Collapse
|
10
|
Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53:164-71. [PMID: 12007956 DOI: 10.1016/s0360-3016(02)02742-6] [Citation(s) in RCA: 113] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE The aim of this study was to evaluate the antitumor efficacy of the novel vascular targeting agent ZD6126 (N-acetylcochinol-O-phosphate) in the rodent KHT sarcoma model, either alone or in combination with single- or fractionated-dose radiation therapy. METHODS C3H/HeJ mice bearing i.m. KHT tumors were injected i.p. with ZD6126 doses ranging from 10 to 150 mg/kg. Tumors were irradiated locally in unanesthetized mice using a linear accelerator. Tumor response to ZD6126 administered alone or in combination with radiation was assessed by clonogenic cell survival assay or tumor growth delay. RESULTS Treatment with ZD6126 led to a rapid tumor vascular shutdown as determined by Hoechst 33342 diffusion. Histologic evaluation showed morphologic damage of tumor cells within a few hours after drug exposure, followed by extensive central tumor necrosis and neoplastic cell death as a result of prolonged ischemia. When combined with radiation, a 150 mg/kg dose of ZD6126 reduced tumor cell survival 10-500-fold compared with radiation alone. These enhancements in tumor cell killing could be achieved for ZD6126 given both before and after radiation exposure. Further, the shape of the cell survival curve observed after the combination therapy suggested that including ZD6126 in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. Finally, when given on a once-weekly basis in conjunction with fractionated radiotherapy, ZD6126 treatment was found to significantly increase the tumor response to daily 2.5 Gy fractions. CONCLUSION The present results demonstrated that in the KHT sarcoma, ZD6126 caused rapid tumor vascular shutdown, induction of central tumor necrosis, tumor cell death secondary to ischemia, and enhancement of the antitumor effects of radiation therapy.
Collapse
Affiliation(s)
- Dietmar W Siemann
- Department of Radiation Oncology, Shands Cancer Center, University of Florida, 2000 SW Archer Road, Box 100385, Gainesville, FL 32610, USA.
| | | |
Collapse
|
11
|
Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR IN BIOMEDICINE 2002; 15:164-173. [PMID: 11870912 DOI: 10.1002/nbm.729] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
We have applied a novel pharmacokinetic model of the distribution of contrast media to dynamic contrast-enhanced MRI data from patients with hepatic neoplasms. The model uses data collected during the passage of a bolus of contrast medium and allows breath-hold image acquisition. The aims of the study were to investigate the feasibility of permeability mapping using the first pass technique and breath-hold acquisitions, and to examine the reproducibility of the technique and the effect of the liver's dual vascular supply on the assumptions of the model. Imaging was performed in 14 patients with hepatic neoplasms. Dynamic data clearly demonstrated differences in the timing and shape of the contrast medium concentration-time course curve in the systemic arterial and portal venous systems. Mapping of the arrival time (T(0)) of contrast medium allowed identification of tissue supplied by the hepatic arteries and portal vein. Hepatic tumours all showed typical hepatic arterial enhancement. Repeated measurements of endothelial permeability surface area product (k(fp)) and relative blood volume (rBV), performed in five patients, showed excellent reproducibility with variance ratios (V(r)) of 0.134 and 0.113, respectively. Measurement of enhancing tumour volume was also highly reproducible (V(r) = 0.096) and this was further improved by the use of T(0) maps to identify pixels supplied by the hepatic artery (V(r) = 0.026). Estimates of k(fp) and rBV in normal hepatic tissue supplied by the portal vein were highly inaccurate and these pixels were identified by use of the T(0) parameter and excluded from the analysis. In conclusion, dynamic MRI contrast enhancement combined with a pharmacokinetic model of the distribution of contrast media in the first pass allows us to produce highly reproducible parametric maps of k(fp) and rBV from hepatic tumours that are supplied by the hepatic arterial system using breath-hold acquisitions.
Collapse
Affiliation(s)
- A Jackson
- Division of Imaging Science and Biomedical Engineering, Stopford Medical School, University of Manchester, Manchester M13 9PT, UK.
| | | | | | | | | | | |
Collapse
|
12
|
Jackson A, Kassner A, Zhu XP, Li KL. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 2001; 14:510-6. [PMID: 11747002 DOI: 10.1002/jmri.1214] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The development of anti-angiogenic therapies for tumors has led to a demand for imaging-based surrogate markers of the angiogenic process. The utility of such markers is highly dependent on their test-retest reproducibility. This paper presents a formal assessment of the reproducibility of measurements of relative blood volume (rBV), normalized rBV (rBVnorm), and vascular tortuosity as estimated by measurement of relative recirculation (rR). The study was conducted in 11 patients with glioma who were scanned on two occasions 36-56 hours apart. The observed reliability estimates were used to calculate 95% confidence limits for detection of differences between groups and for changes in individual cases. The results show that measurement of rBV or rBVnorm in consecutive studies is statistically capable of reliably detecting changes in excess of 15% in between group studies and 25% in individual patients. Measurement of vascular tortuosity using is less reproducible but is able to confidently identify changes in excess of 30% in group studies and 35% in individuals.
Collapse
Affiliation(s)
- A Jackson
- Imaging Science and Biomedical Engineering, University of Manchester, UK.
| | | | | | | |
Collapse
|
13
|
Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001; 163:191-200. [PMID: 11165754 DOI: 10.1016/s0304-3835(00)00701-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Angiogenesis is an essential process for the growth and invasion of cancer. However, it is uncertain that anti-angiogenic effects can be a major treatment strategy of oral cancer. The aim of this study was to investigate whether thalidomide and paclitaxel, which are known to be potent inhibitors of angiogenesis, have inhibitory effects on the growth of oral squamous cell carcinoma (OSCC) xenotransplanted into nude mice and whether anti-angiogenesis can be included as a major treatment strategy of oral cancer. After human OSCC cell line, KB, was subcutaneously inoculated into 32 nude mice, the volume of tumor was measured every 3 days. When the tumor mass reached 300-500 mm3, thalidomide (200 mg/kg) and paclitaxel (13 mg/kg) were administered into the animals and tumor volume change was checked. The excised tumor masses on the 30th day after administration were frozen and processed for immunohistochemistry using vascular endothelial growth factor (VEGF) and CD31, and for real-time reverse transcription-polymerase chain reaction (RT-PCR). We evaluated VEGF expression and the expression of its mRNA and CD31 for vessel density. Paclitaxel showed an inhibitory effect on the growth of transplanted human OSCC and reduced the immunohistochemical expression of VEGF and CD31 and VEGF mRNA (P<0.01). Thalidomide also lowered remarkably VEGF expression (P<0.01) and CD31 (P<0.01) as well as VEGF mRNA (P<0.05), but it did not show statistically significant inhibitory effect on the tumor growth. These results suggest that the growth of human OSCC is not simply dependent on VEGF-induced angiogenesis and that anti-angiogenic therapy alone is not likely to be effective for the treatment of OSCC, but might be regarded as adjuvant chemotherapeutic strategy.
Collapse
MESH Headings
- Angiogenesis Inhibitors/therapeutic use
- Animals
- Antineoplastic Agents, Phytogenic/therapeutic use
- Carcinoma, Squamous Cell/blood supply
- Carcinoma, Squamous Cell/metabolism
- Carcinoma, Squamous Cell/prevention & control
- Drug Screening Assays, Antitumor
- Drug Therapy, Combination
- Endothelial Growth Factors/metabolism
- Female
- Humans
- Lymphokines/metabolism
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mouth Neoplasms/blood supply
- Mouth Neoplasms/metabolism
- Mouth Neoplasms/prevention & control
- Neoplasm Transplantation
- Neovascularization, Pathologic/metabolism
- Neovascularization, Pathologic/prevention & control
- Paclitaxel/therapeutic use
- RNA, Messenger/metabolism
- Thalidomide/therapeutic use
- Transplantation, Heterologous
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
Collapse
Affiliation(s)
- H Myoung
- Department of Oral and Maxillofacial Surgery, College of Dentistry and Dental Research Institute, Seoul National University, 28-2, Yun-Gun dong, Chong-No gu, Seoul, South Korea
| | | | | | | | | |
Collapse
|
14
|
Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42:899-903. [PMID: 9845118 DOI: 10.1016/s0360-3016(98)00320-4] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE The aim of this study was to evaluate the antitumor efficacy of combretastatin A-4 disodium phosphate (combretastatin prodrug) in the rodent KHT sarcoma model either alone or in combination with radiation therapy. METHODS KHT tumors were grown in C3H/HeJ mice. Combretastatin A-4 prodrug was injected intraperitoneally at doses ranging from 10 to 100 mg/kg. Tumors were irradiated in unanesthetized mice using a 137Cs source. Tumor response to combretastatin A-4 prodrug was assessed by histological evaluations as well as an in vivo to in vitro cell survival assay. RESULTS Histological evaluation showed morphological damage of tumor cells within a few hours after drug treatment, followed by extensive central necrosis. Administering increasing doses of combretastatin A-4 prodrug to tumor-bearing mice resulted in a dose-dependent increase in cell killing irrespective of whether the tumors were irradiated or not. When combined with radiation, a 100 mg/kg dose of combretastatin A-4 prodrug reduced tumor cell survival 10-500-fold lower than that seen with radiation alone. Further, the shape of the cell survival curve observed following the combination therapy suggested that including combretastatin in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. CONCLUSION The present results demonstrated that in the KHT sarcoma, combretastatin A-4 prodrug caused rapid vascular shutdown, a concentration-dependent direct cell killing, and effective enhancement of the antitumor effects of radiation therapy.
Collapse
Affiliation(s)
- L Li
- Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville 32610, USA
| | | | | |
Collapse
|
15
|
Affiliation(s)
- R G Favaloro
- Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation, Buenos Aires, Argentina.
| |
Collapse
|